DEPLOYThe reference layer for physical AI

Robot model

Withings ScanWatch

Withings, a French consumer-health-electronics company founded in 2008 and independent again since 2018 after being bought back from Nokia, makes the ScanWatch line of biometric-primary hybrid analog smartwatches with cardiac and respiratory AI augmentation, recorded in the new biometric form factor. The ScanWatch 2 and ScanWatch Nova pair an analog dial with optical heart-rate, electrical ECG, blood-oxygen, and continuous temperature sensors on roughly a 30-day battery. Their FDA clearances are the ECG app, cleared in October 2021 to classify atrial fibrillation, sinus rhythm, and high heart rate for adults 22 and older, updated in July 2025 so that the ScanWatch 2 ECG is cleared over the counter, no longer requiring a board-certified cardiologist to activate, with a new eight-classification atrial-fibrillation algorithm, plus a cleared blood-oxygen feature that supports tracking breathing disturbances at night. A cap-flag applies because the breathing-disturbance detection is a screening aid rather than a sleep-apnea diagnosis, and framing it as diagnosis exceeds scope. Withings offers a clean contrast to Apple, since its blood-oxygen and ECG features were never disabled in the US as it is not party to the Masimo dispute, and the notable 2025 regulatory event was a positive over-the-counter liberalization rather than a restriction. It sells by hardware purchase with an optional Withings+ membership, its clinical-validation posture is substantial for its size with strong study framing and CE medical marking, and the exact clearance numbers and dates for the ScanWatch 2 blood-oxygen and temperature features and the standard US list prices are approximate and not fully verified.

Withings ScanWatch is a biometric robot built by

Machine-readable surfaces

Form factor
biometric
Maturity stage
commercial
Lifecycle
active
Deployments
0
ID
7b714434-e448-4dd4-8302-98627a94db3b

Specs

notes
[object Object],[object Object],[object Object]
specs
ScanWatch 2 (~$349) + ScanWatch Nova (Nova Brilliant $599.95, Nov 2024). Hybrid analog-dial + sensor watches: PPG optical HR, electrical ECG, SpO2, TempTech24/7 continuous temperature; ~30-day battery. AI/health: ECG (AFib/sinus/high-HR), SpO2 + breathing-disturbance detection, temperature trends. Founded 2008, France (Issy-les-Moulineaux); independent since 2018 (bought back from Nokia). Hardware purchase; Withings+ ($9.95/mo) optional.
formFactor
biometric (biometric-primary hybrid analog smartwatch + AI; ECG/SpO2 cleared)

Supply chain

No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.

Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.

Sources (4)

  1. https://en.wikipedia.org/wiki/Withings
  2. https://support.withings.com/hc/en-us/articles/16780197080209-ScanWatch-2-ECG-Frequently-Asked-Questions-FAQ-U-S-Only
  3. https://support.withings.com/hc/en-us/articles/36773695647249-ScanWatch-2-ECG-Update-2025-U-S
  4. https://sleepreviewmag.com/sleep-diagnostics/consumer-sleep-tracking/wearable-sleep-trackers/fda-clears-withings-scanwatch-spo2/

Common questions

What is Withings ScanWatch?
Withings, a French consumer-health-electronics company founded in 2008 and independent again since 2018 after being bought back from Nokia, makes the ScanWatch line of biometric-primary hybrid analog smartwatches with cardiac and respiratory AI augmentation, recorded in the new biometric form factor. The ScanWatch 2 and ScanWatch Nova pair an analog dial with optical heart-rate, electrical ECG, blood-oxygen, and continuous temperature sensors on roughly a 30-day battery. Their FDA clearances are the ECG app, cleared in October 2021 to classify atrial fibrillation, sinus rhythm, and high heart rate for adults 22 and older, updated in July 2025 so that the ScanWatch 2 ECG is cleared over the counter, no longer requiring a board-certified cardiologist to activate, with a new eight-classification atrial-fibrillation algorithm, plus a cleared blood-oxygen feature that supports tracking breathing disturbances at night. A cap-flag applies because the breathing-disturbance detection is a screening aid rather than a sleep-apnea diagnosis, and framing it as diagnosis exceeds scope. Withings offers a clean contrast to Apple, since its blood-oxygen and ECG features were never disabled in the US as it is not party to the Masimo dispute, and the notable 2025 regulatory event was a positive over-the-counter liberalization rather than a restriction. It sells by hardware purchase with an optional Withings+ membership, its clinical-validation posture is substantial for its size with strong study framing and CE medical marking, and the exact clearance numbers and dates for the ScanWatch 2 blood-oxygen and temperature features and the standard US list prices are approximate and not fully verified.
Who makes Withings ScanWatch?
Withings ScanWatch is made by Withings, based in Issy-les-Moulineaux, France, founded in 2008.
Where is Withings ScanWatch deployed?
No verified deployments of Withings ScanWatch are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
What is Withings ScanWatch's maturity stage?
Withings ScanWatch is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.